Clinical Trials List
2022-02-01 - 2028-07-31
Phase II
Recruiting1
ICD-10E70.20
Disorder of tyrosine metabolism, unspecified
ICD-10E70.21
Tyrosinemia
ICD-10E70.29
Other disorders of tyrosine metabolism
ICD-10E70.30
Albinism, unspecified
ICD-10E70.310
X-linked ocular albinism
ICD-10E70.311
Autosomal recessive ocular albinism
ICD-10E70.318
Other ocular albinism
ICD-10E70.319
Ocular albinism, unspecified
ICD-10E70.320
Tyrosinase negative oculocutaneous albinism
ICD-10E70.321
Tyrosinase positive oculocutaneous albinism
ICD-10E70.328
Other oculocutaneous albinism
ICD-10E70.329
Oculocutaneous albinism, unspecified
ICD-10E70.330
Chediak-Higashi syndrome
ICD-10E70.331
Hermansky-Pudlak syndrome
ICD-10E70.338
Other albinism with hematologic abnormality
ICD-10E70.339
Albinism with hematologic abnormality, unspecified
ICD-10E70.39
Other specified albinism
ICD-10E70.5
Disorders of tryptophan metabolism
ICD-10E70.8
Other disorders of aromatic amino-acid metabolism
ICD-10E70.9
Disorder of aromatic amino-acid metabolism, unspecified
ICD-9270.2
Other disturbances of aromatic amino-acid metabolism
-
Trial Applicant
台灣喜帝諮詢顧問有限公司
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2025/08/20
Investigators and Locations
Co-Principal Investigator
- 周聖哲 Division of Orthopedics
- 徐瑞聲 Division of General Internal Medicine
- CHUN-HWEI TAI Division of Neurology
- 陳薈安 Division of Pediatrics
- WUH-LIANG HWU Division of Pediatrics
- 彭信逢 Division of Radiology
- NI-CHUNG LEE Division of Pediatrics
- 柯紀綸 Division of Nuclear Medicine
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
5 participants
-
Global
13 participants
